Journal of Drug Targeting最新文献_第10页

Control of skin carcinoma via sonidegib-loaded transbilosomes. 载sonidegib的跨胆囊体对皮肤癌的控制。

IF 4.7 4区医学

Journal of Drug Targeting Pub Date : 2026-08-04 DOI: 10.1080/1061186X.2026.2709767

Rowayda Mohamed Ahmed, Maha M Ghalwash, Amr Gamal Fouad, Randa Mohammed Zaki, Obaid Afzal, Rawan Bafail, Waad A Samman, Asmaa M El-Kalaawy, Alshimaa Mohamed Abdelmohymen, Mai Abdou Yousef

{"title":"Control of skin carcinoma via sonidegib-loaded transbilosomes.","authors":"Rowayda Mohamed Ahmed, Maha M Ghalwash, Amr Gamal Fouad, Randa Mohammed Zaki, Obaid Afzal, Rawan Bafail, Waad A Samman, Asmaa M El-Kalaawy, Alshimaa Mohamed Abdelmohymen, Mai Abdou Yousef","doi":"10.1080/1061186X.2026.2709767","DOIUrl":"10.1080/1061186X.2026.2709767","url":null,"abstract":"The uncontrolled proliferation of abnormal skin cells is the hallmark of skin carcinoma. Sonidegib (SDB), a potent Hedgehog pathway inhibitor, is clinically approved for the treatment of skin carcinoma. However, its therapeutic utility is restricted by poor bioavailability, high hydrophobicity, and significant systemic adverse effects. This study aimed to develop an intratumor SDB-loaded transbilosomes (SLT) formulation to improve localised therapeutic efficacy and mitigate systemic toxicity. Several SLT formulations were developed and optimised using Design-Expert® software. The optimised SLT formulation was evaluated for safety, intratumor retention, and efficacy using a DMBA-induced skin carcinoma rat model. Results demonstrated that the optimal SLT formulation achieved a 68.87% reduction in drug release after 24 h compared to free SDB. Pharmacokinetic evaluation revealed a 7.78-fold increase in relative systemic bioavailability compared to oral SDB. In vivo efficacy studies showed an 84.22% reduction in tumour volume in the intratumor SLT-treated group, with no observed fatalities compared to the oral SDB. Histopathological and safety assessments confirmed the significant antiproliferative effects and the favourable preliminary safety profile of the intratumor SLT formulation. These findings suggest that the intratumor SLT formulation provides an effective option for the management of skin carcinoma.","PeriodicalId":15573,"journal":{"name":"Journal of Drug Targeting","volume":" ","pages":"1-12"},"PeriodicalIF":4.7,"publicationDate":"2026-08-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148578708","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Buspirone hydrochloride: a potential regulator of PD-L1 for enhanced antitumor activity in melanoma-bearing mice. 丁螺环酮盐酸盐：PD-L1增强黑色素瘤小鼠抗肿瘤活性的潜在调节剂。

IF 4.7 4区医学

Journal of Drug Targeting Pub Date : 2026-08-01 Epub Date: 2026-01-12 DOI: 10.1080/1061186X.2025.2611944

Jiaxin Geng, Kangle Wang, Sheping Zhang, Xiaofei Cheng, Chifei Zhang, Mingyu Mo, Xingchan Ji, Mingguang Shao, Hanyu Jiang, Mengyu Lei, Sheng Guo, Zishan Yang, Yongxi Zhang, Tian Wei, Zhongwei Tian, Yinghua Ji, Tiesuo Zhao, Huijie Jia

{"title":"Buspirone hydrochloride: a potential regulator of PD-L1 for enhanced antitumor activity in melanoma-bearing mice.","authors":"Jiaxin Geng, Kangle Wang, Sheping Zhang, Xiaofei Cheng, Chifei Zhang, Mingyu Mo, Xingchan Ji, Mingguang Shao, Hanyu Jiang, Mengyu Lei, Sheng Guo, Zishan Yang, Yongxi Zhang, Tian Wei, Zhongwei Tian, Yinghua Ji, Tiesuo Zhao, Huijie Jia","doi":"10.1080/1061186X.2025.2611944","DOIUrl":"10.1080/1061186X.2025.2611944","url":null,"abstract":"PD-1/PD-L1 blockade therapy shows good efficacy in melanoma treatment. Yet, most patients still exhibit poor responses. Exploring more effective drugs remains worthwhile. In contrast to developing new drugs which entails a lengthy process, high costs and uncertainties, repurposing old drugs is regarded as a promising and safe method, attracting greater attention. In this study, we evaluated the anti-melanoma effect of buspirone hydrochloride, a novel anti-anxiety drug. The results demonstrated that buspirone hydrochloride effectively restrained cell proliferation and migration and decreased the expression of related proteins p-STAT3, cyclin D1 and MMP2. Significantly, we discovered that buspirone hydrochloride efficiently enhanced the degradation of PD-L1. Further investigations in a melanoma-bearing mouse model showed that buspirone hydrochloride delayed the growth of tumours in tumour-bearing mice, increased apoptosis of tumour cells and inhibited cell proliferation. We found that buspirone hydrochloride treatment increased the ratio of T lymphocytes in the spleen of mice and the infiltration of T lymphocytes in tumour tissues. These findings suggest that buspirone hydrochloride not only plays an anti-melanoma role by directly inhibiting cell proliferation and promoting apoptosis but also enhances the anti-tumour immune response by suppressing PD-L1 expression, thus providing a new alternative for the development of melanoma treatment drugs.","PeriodicalId":15573,"journal":{"name":"Journal of Drug Targeting","volume":" ","pages":"1301-1314"},"PeriodicalIF":4.7,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145900600","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Modified proposomes as a novel intra-articular delivery approach for rheumatoid arthritis. 类风湿关节炎关节内给药新途径的改良建议。

IF 4.7 4区医学

Journal of Drug Targeting Pub Date : 2026-08-01 Epub Date: 2026-01-16 DOI: 10.1080/1061186X.2025.2607393

Moataz B Zewail, Gihan F Asaad, Sally A El Awdan, Marwa E Shabana, Walaa A El-Dakroury

{"title":"Modified proposomes as a novel intra-articular delivery approach for rheumatoid arthritis.","authors":"Moataz B Zewail, Gihan F Asaad, Sally A El Awdan, Marwa E Shabana, Walaa A El-Dakroury","doi":"10.1080/1061186X.2025.2607393","DOIUrl":"10.1080/1061186X.2025.2607393","url":null,"abstract":"A novel intra-articular (IA) nanocarrier system for leflunomide (LEF) was developed using modified proposomes to enhance therapeutic efficacy in rheumatoid arthritis (RA). LEF was efficiently encapsulated within propylene glycol-based proposomes, which were sequentially functionalised with chitosan (CS) and hyaluronic acid (HA) to improve stability, bioadhesion and targeted delivery. The optimised nanoparticles exhibited a uniform nanoscale size, a zeta potential of -50.46 ± 6.4 mV, and a high entrapment efficiency of 94.12 ± 1.7%. In vitro release studies revealed a sustained LEF release profile from LEF-HA-proposomes over 84 h. In a Complete Freund's adjuvant (CFA)-induced RA rat model, IA administration of LEF-HA-proposomes resulted in marked therapeutic improvements (P˂0.05), including a 39.24% reduction in paw edoema, a 3.26-fold decrease in rheumatoid factor, a 3.47-fold reduction in TNF-α, and a 4.75-fold decline in IL-1β levels, accompanied by a 2.73-fold elevation in Nrf2 expression. Histopathological evaluation confirmed significant preservation of joint architecture and attenuation of synovial inflammation in the LEF-HA-proposomes group. Collectively, these findings highlight LEF-HA-proposomes as a promising IA nanocarrier platform for targeted RA therapy, offering prolonged drug retention, enhanced local anti-inflammatory efficacy, and minimised systemic toxicity compared with conventional oral treatments.","PeriodicalId":15573,"journal":{"name":"Journal of Drug Targeting","volume":" ","pages":"1246-1262"},"PeriodicalIF":4.7,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145970779","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Synergistic antibacterial and antibiofilm activity of N-acetylcysteine combined with niosomal recombinant lysostaphin against MRSA Staphylococcus aureus. n -乙酰半胱氨酸联合Niosomal重组溶葡萄球菌对MRSA金黄色葡萄球菌的协同抗菌活性研究。

IF 4.7 4区医学

Journal of Drug Targeting Pub Date : 2026-08-01 Epub Date: 2026-01-01 DOI: 10.1080/1061186X.2025.2607397

Hadis Sadri, Nader Shahrokhi, Mina Ebrahimi-Rad, Masoud Mardani, Somayeh Sadeghi, Mohammad Pooya

{"title":"Synergistic antibacterial and antibiofilm activity of N-acetylcysteine combined with niosomal recombinant lysostaphin against MRSA Staphylococcus aureus.","authors":"Hadis Sadri, Nader Shahrokhi, Mina Ebrahimi-Rad, Masoud Mardani, Somayeh Sadeghi, Mohammad Pooya","doi":"10.1080/1061186X.2025.2607397","DOIUrl":"10.1080/1061186X.2025.2607397","url":null,"abstract":"Wound infections significantly impair healing and often result in chronic wounds, burdening healthcare systems substantially. The principal pathogen in such infections is Staphylococcus aureus (S. aureus), which forms biofilms that resist host defences and conventional therapies. To overcome these challenges, recombinant lysostaphin (rLyso) was encapsulated in niosomes using thin-film hydration and evaluated with N-acetylcysteine (NAC) against standard and clinical S. aureus strains. Antibacterial and antibiofilm activities were assessed by determining the minimum inhibitory concentration (MIC) and minimum biofilm eradication concentration (MBEC), complemented by fluorescence and confocal microscopy. Cytotoxicity was assessed in L929 fibroblasts, and in vivo efficacy was investigated in BALB/c mouse wound models. The NAC/niosomal rLyso formulation exhibited the most potent antibacterial and antibiofilm effects, significantly lowering the MIC values (standard: 1250/5.9 μg/ml; clinical: 1250/2 μg/ml) and achieving notable biofilm eradication (MBEC: standard: 5000/23.6 μg/ml; clinical: 1250/2 μg/ml). Cytotoxicity assays confirmed high bio-compatibility, with nearly 100% cell viability at MIC, while NAC alone was highly toxic. The combination of two agents achieved full bacterial clearance in vivo and accelerated wound healing. These findings suggest that NAC combined with niosomal rLyso synergistically disrupts S. aureus biofilms, enhances antimicrobial activity, and promotes wound repair, making it a promising therapeutic strategy against resistant staphylococcal infections.","PeriodicalId":15573,"journal":{"name":"Journal of Drug Targeting","volume":" ","pages":"1263-1276"},"PeriodicalIF":4.7,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145804796","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Delivery of disulphiram by copper-doped mesoporous silica nanoparticles in combination with doxycycline for treating colorectal cancer liver metastasis. 铜掺杂介孔二氧化硅纳米颗粒联合强力霉素递送双硫仑治疗大肠癌肝转移。

IF 4.7 4区医学

Journal of Drug Targeting Pub Date : 2026-08-01 Epub Date: 2026-01-12 DOI: 10.1080/1061186X.2025.2608805

Yidan Zhang, Bin Xiong, Siyan Zhang, Qi Meng, Yunzhu Tian, Xin Jin, Shougang Jiang

{"title":"Delivery of disulphiram by copper-doped mesoporous silica nanoparticles in combination with doxycycline for treating colorectal cancer liver metastasis.","authors":"Yidan Zhang, Bin Xiong, Siyan Zhang, Qi Meng, Yunzhu Tian, Xin Jin, Shougang Jiang","doi":"10.1080/1061186X.2025.2608805","DOIUrl":"10.1080/1061186X.2025.2608805","url":null,"abstract":"Colorectal cancer liver metastasis (CCLM) remains a major therapeutic challenge due to chemoresistance and dose-limiting toxicities of conventional therapies. This study developed a copper-doped mesoporous silica nanoparticle (DSF@Cu-MSNs-BSA) for co-delivering disulphiram (DSF) and doxycycline (DOX) to synergistically target CCLM. The nanocomposite was synthesised via Sol-gel co-condensation, surface amination, and albumin adsorption, achieving a high DSF loading capacity (12.69 ± 2.47% w/w) with sustained release. Physicochemical characterisation confirmed uniform spherical morphology (160.8 ± 20.7 nm), Cu2+ incorporation (4.74% atomic ratio), and exceptional colloidal stability (>24 h). In vitro studies demonstrated synergistic cytotoxicity in CT26.WT cells, with combination therapy reducing IC50 by 2.5-fold versus monotherapes (p < 0.01), mediated by ROS overproduction (6.7-fold vs control) and mitochondrial depolarisation. Pharmacological ROS quenching attenuated cytotoxicity by 46.5%, validating redox-driven mechanisms. In an orthotopic CCLM model, DSF@Cu-MSNs-BSA/DOX combination suppressed hepatic metastasis by 72-75%, extending median survival by 51% versus control (p < 0.01), comparable to capecitabine (p > 0.05). Histopathology revealed minimal metastatic burden and reduced hepatotoxicity in combinatorial groups. The Goldie-Coldman synergy index (q = 1.18) confirmed supra-additive efficacy. This nanoplatform addresses DSF's pharmacokinetic limitations while leveraging DOX's mitochondrial targeting, offering a promising strategy for metastatic CRC management with favourable safety profiles.","PeriodicalId":15573,"journal":{"name":"Journal of Drug Targeting","volume":" ","pages":"1277-1290"},"PeriodicalIF":4.7,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145933452","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Recent advances in theranostic-based extracellular vesicles in cancer stem cell diagnosis and therapy. 基于治疗学的细胞外囊泡在肿瘤干细胞诊断和治疗中的最新进展。

IF 4.7 4区医学

Journal of Drug Targeting Pub Date : 2026-08-01 Epub Date: 2026-01-09 DOI: 10.1080/1061186X.2025.2609201

Yunlan Huang, Linlin Chang, He Wang, Huiyang Sun, Yibin Feng, Dongqing Li

{"title":"Recent advances in theranostic-based extracellular vesicles in cancer stem cell diagnosis and therapy.","authors":"Yunlan Huang, Linlin Chang, He Wang, Huiyang Sun, Yibin Feng, Dongqing Li","doi":"10.1080/1061186X.2025.2609201","DOIUrl":"10.1080/1061186X.2025.2609201","url":null,"abstract":"Cancer remains a leading cause of mortality worldwide, with treatment failure and disease recurrence often driven by cancer stem cells (CSCs), which constitute a resilient subpopulation within tumours characterised by self-renewal, differentiation capacity and resistance to conventional therapies. Extracellular vesicles (EVs), including exosomes and microvesicles, are secreted by CSCs and play pivotal roles in tumour progression, immune evasion and therapeutic resistance by transporting bioactive molecules such as heat shock proteins and regulatory RNAs. These vesicles reflect the molecular signature of their parent cells and offer unique opportunities for non-invasive diagnostics and targeted therapy. The theranostic paradigm, which integrates diagnostic and therapeutic functions, leverages EVs for CSC-specific biomarker detection, drug delivery and real-time monitoring of treatment response. Advances in nanotechnology and molecular engineering have enabled the functionalization of EVs with imaging agents and therapeutic payloads, increasing their specificity and efficacy in preclinical and early clinical settings. This narrative review synthesises current knowledge on CSC biology, EV biogenesis and the evolving landscape of EV-based theranostics, highlighting translational progress, technical challenges and future directions. Theranostic EVs represent a promising frontier in precision oncology, offering transformative potential for the management of CSC-driven tumorigenesis and relapse.","PeriodicalId":15573,"journal":{"name":"Journal of Drug Targeting","volume":" ","pages":"1105-1115"},"PeriodicalIF":4.7,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145819573","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Therapeutic effects of fluorescent gabapentin carbon quantum dots on pentylenetetrazol-induced seizures in rats. 加巴喷丁荧光碳量子点对戊四唑致大鼠癫痫发作的治疗作用。

IF 4.7 4区医学

Journal of Drug Targeting Pub Date : 2026-08-01 Epub Date: 2026-01-02 DOI: 10.1080/1061186X.2025.2602661

Ayşe Özçetin, Hüseyin Koyuncu, Gamze Camlik, Burcu Çevreli, Zeynep Kocaizmirli, Ismail Tuncer Degim, Tayfun Uzbay

{"title":"Therapeutic effects of fluorescent gabapentin carbon quantum dots on pentylenetetrazol-induced seizures in rats.","authors":"Ayşe Özçetin, Hüseyin Koyuncu, Gamze Camlik, Burcu Çevreli, Zeynep Kocaizmirli, Ismail Tuncer Degim, Tayfun Uzbay","doi":"10.1080/1061186X.2025.2602661","DOIUrl":"10.1080/1061186X.2025.2602661","url":null,"abstract":"We aimed to synthesise carbon quantum dots (CQDs) from the active molecule gabapentin (GBP) and to evaluate their effects on pentylenetetrazol (PTZ)-induced seizures in rats. Gabapentin CQDs (GBPCQDs) were synthesised using a rapid, one-pot microwave-assisted method and characterised by particle size, polydispersity index, zeta potential and fluorescence properties. Adult male Wistar rats received GBP or GBPCQDs (15, 30, 60 or 120 mg/kg, intraperitoneally) 30 min before PTZ administration (50 mg/kg). Seizure onset times and severity were assessed, and locomotor activity was evaluated at the most effective doses. While GBP did not significantly affect seizure onset, GBPCQDs at 15 mg/kg significantly prolonged the onset time of PTZ-induced seizures. Both GBP and GBPCQDs significantly reduced seizure severity at all tested doses, however, GBPCQDs at 60 and 120 mg/kg were more effective than the corresponding doses of GBP. Neither treatment produced significant changes in locomotor activity. Fluorescence imaging demonstrated the presence of GBPCQDs in the prefrontal cortex, striatum and hippocampus, with the highest fluorescence intensity observed in the prefrontal cortex. These findings indicate that GBPCQDs may provide therapeutic advantages over conventional GBP and represent a promising fluorescent nanocarrier for brain-targeted drug delivery in epilepsy.","PeriodicalId":15573,"journal":{"name":"Journal of Drug Targeting","volume":" ","pages":"1224-1233"},"PeriodicalIF":4.7,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145723908","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Mitochondria-targeted nanocarriers for smart response delivery of natural products: a review. 天然产物智能响应递送的线粒体靶向纳米载体：综述。

IF 4.7 4区医学

Journal of Drug Targeting Pub Date : 2026-08-01 Epub Date: 2026-01-12 DOI: 10.1080/1061186X.2025.2611940

Jiansheng Cao, Wenfei Lu, Ying Lv, Meng Li, Ye Tang, Yufei Feng

{"title":"Mitochondria-targeted nanocarriers for smart response delivery of natural products: a review.","authors":"Jiansheng Cao, Wenfei Lu, Ying Lv, Meng Li, Ye Tang, Yufei Feng","doi":"10.1080/1061186X.2025.2611940","DOIUrl":"10.1080/1061186X.2025.2611940","url":null,"abstract":"Mitochondrial dysfunction is closely associated with the onset and progression of various major diseases, including cancer and neurodegenerative disorders. The design of smart nanomaterial-natural product composite systems offers an innovative strategy for multifunctional nanocarriers. These smart carriers not only enable precise, controlled release of active components at specific mitochondrial targets but also provide novel technical support for natural products to overcome various barriers encountered during in vivo administration, thereby enhancing bioavailability. This review systematically summarises the latest research advances in mitochondria-targeted nano-drug delivery systems based on smart responsive principles for delivering natural products. It focuses on exploring the design principles, mechanisms of action, and representative applications of various responsive systems (including pH-, enzyme-, redox-, temperature-, light-, magnetic-, and ultrasound-responsive systems). Furthermore, existing challenges and unexplored therapeutic opportunities through interdisciplinary strategies integrating AI technology, CRISPR gene editing, and biomimetic materials are also highlighted and discussed to inspire the next generation of mitochondrial-targeted nanotherapeutics.","PeriodicalId":15573,"journal":{"name":"Journal of Drug Targeting","volume":" ","pages":"1116-1132"},"PeriodicalIF":4.7,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145933393","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

SKQ1: a mitochondria-targeted antioxidant with therapeutic potential. SKQ1：一种具有治疗潜力的线粒体靶向抗氧化剂。

IF 4.7 4区医学

Journal of Drug Targeting Pub Date : 2026-08-01 Epub Date: 2026-01-14 DOI: 10.1080/1061186X.2026.2613054

Ruolan Wu, Yuan Wu

引用次数: 0

Nanovesicles-enabled concurrent delivery of cyclosporine and Vitamin D for topical treatment of psoriasis. 纳米囊泡使环孢素和维生素D同时递送用于局部治疗银屑病。

IF 4.7 4区医学

Journal of Drug Targeting Pub Date : 2026-08-01 Epub Date: 2025-12-22 DOI: 10.1080/1061186X.2025.2604148

Kailas Moravkar, Vishakha Ipar, Kalpesh R Patil, Shailesh Chalikwar, Pradip Nirbhavane

{"title":"Nanovesicles-enabled concurrent delivery of cyclosporine and Vitamin D for topical treatment of psoriasis.","authors":"Kailas Moravkar, Vishakha Ipar, Kalpesh R Patil, Shailesh Chalikwar, Pradip Nirbhavane","doi":"10.1080/1061186X.2025.2604148","DOIUrl":"10.1080/1061186X.2025.2604148","url":null,"abstract":"Psoriasis is a chronic autoimmune skin disease, which affects the quality of life of patients. Cyclosporine (Cys-A) & Vitamin D (Vit D3) are crucial drugs used in the treatment of the disease. They are mainly administered via oral dosage forms for the treatment of psoriasis. However, their conventional dosage forms suffer from low oral bioavailability, along with systemic adverse effects. Developing the topical dosage forms of these drugs can be advantageous to overcome the problems associated with conventional therapy. Hence, ethosomes (ETH) were developed for the simultaneous administration of both the drugs. The particle size of the developed ethosomes was found to be 120.8 ± 5.6 nm, zeta potential value was found to be -24.7 ± 1.5 and entrapment efficiency was found to be 74.8 ± 1.52% & 80 ± 1.8% respectively, for Cys-A and Vit D3. In vitro drug release studies exhibited drug release of about 74% and 78% for Cys-A & Vit D3, respectively. Skin permeation studies demonstrated significantly higher drug permeation of ETH gel for Cys-A & Vit-D3 (71.6% and 72.2% respectively) than the conventional gel formulation (52.9% and 54.8% respectively). A cytotoxicity study conducted on the HaCaT cell line showed no cytotoxicity with ≥ 90% of cell viability. The therapeutic efficacy of the formulation tested on the in-vivo antipsoriatic rat model demonstrated comparable efficacy to that of the marketed formulation and the signs of inflammation were reverted within 14 days.","PeriodicalId":15573,"journal":{"name":"Journal of Drug Targeting","volume":" ","pages":"1234-1245"},"PeriodicalIF":4.7,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145756777","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0